SAB Biotherapeutics, Inc. (SABS)
3.71
-0.08
(-2.11%)
USD |
NASDAQ |
Aug 31, 16:00
3.715
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Total Liabilities (Quarterly) : 23.42M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.42M |
| March 31, 2026 | 21.22M |
| December 31, 2025 | 23.02M |
| September 30, 2025 | 18.37M |
| June 30, 2025 | 18.11M |
| March 31, 2025 | 16.71M |
| December 31, 2024 | 20.09M |
| September 30, 2024 | 16.89M |
| June 30, 2024 | 15.77M |
| March 31, 2024 | 18.55M |
| December 31, 2023 | 26.64M |
| September 30, 2023 | 13.08M |
| Date | Value |
|---|---|
| June 30, 2023 | 15.73M |
| March 31, 2023 | 18.27M |
| December 31, 2022 | 19.85M |
| September 30, 2022 | 21.88M |
| June 30, 2022 | 22.03M |
| March 31, 2022 | 26.21M |
| December 31, 2021 | 42.59M |
| September 30, 2021 | 10.07M |
| June 30, 2021 | 9.904M |
| March 31, 2021 | 7.883M |
| December 31, 2020 | 0.3062M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 238.21M |
| Shareholders Equity (Quarterly) | 214.78M |
| Debt to Equity Ratio | 0.0239 |
| Current Ratio | 9.221 |
| Net Debt Paydown Yield | 0.10% |